Evidence-Based Answers

Evidence Central™ is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research.


Evidence Central for Mobile Devices

Evidence Central iOS iPhone iPad Android

Evidence Central from Unbound Medicine, available for iOS® and Android™, is optimized for each platform and features superior navigation, so answers are easy to find at the bedside or anywhere they’re needed. Learn More

Word of the Day

Bimatoprost (Latisse) enhances eyelash growth and prominence

Clinical Question:
Is bimatoprost 0.03% effective in enhancing the growth and prominence of eyelashes?

Bottom Line:
Bimatoprost 0.03% (Latisse) is effective in enhancing the growth and prominence of eyelashes. (LOE = 1b)

Smith S, Fagien S, Whitcup SM, et al. Eyelash growth in subjects treated with bimatoprost: A multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol 2012;66(5):801-806.  [PMID:21899919]

Study Design:
Randomized controlled trial (double-blinded)



Outpatient (specialty)

Bimatoprost ophthalmic solution 0.03% is effective in reducing elevated intraocular pressure. However, patients frequently report eyelash growth as a side effect. These investigators identified 278 consenting adults desirous of longer eyelashes, 18 years or older, with a global eyelash assessment (GEA) score of 1 or 2. A GEA score of 1 indicates none to minimal eyelash growth, with 2, 3, and 4 indicating moderate, marked, and very marked eyelash growth, respectively. Patients applied 1 drop of bimatoprost 0.03% (Latisse) or identical vehicle only (concealed allocation assignment) along each upper eyelid margin nightly for 4 months. Individuals assessing outcomes remained masked to treatment group assignment. Complete follow-up occurred for 92.4% of patients at 4 months. Using intention-to-treat analysis, eyelash prominence scored as marked or very marked (GEA score 3 or 4) occurred significantly more often in bimatoprost-treated patients than in the control patients (67.2% vs 12.1%, respectively; number needed to treat = 1.8; 95% CI,1.6-2.2). Patients using bimatoprost reported conjunctival hyperemia significantly more often than those in the control group, but discontinuation rates due to adverse events were similar. No significant iris pigmentation changes were reported.


Site Licenses

Site license

Site Licenses are available for schools, universities, hospitals, government agencies, and companies. For more information, contact us.